A Phase 2b/3 trial of Atumelnant in pediatric patients
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Atumelnant (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 According to Crinetics Pharmaceuticals media release, company expect to start a Phase 2b/3 trial in pediatric patients this year.